Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents

Regeneron Pharmaceuticals, Tarrytown, NY, USA.
Cancer and metastasis reviews (Impact Factor: 7.23). 07/2006; 25(2):243-52. DOI: 10.1007/s10555-006-8504-6
Source: PubMed
8 Reads

  • The International Journal of Lower Extremity Wounds 04/2007; 6(1):8-10. DOI:10.1177/1534734607299180 · 0.93 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Analysis of the lymphatic microvasculature has become possible only recently by the discovery of novel proteins specifically expressed in lymphatic endothelial cells only. Therapeutic manipulation of de novo lymphangiogenesis might become clinically relevant in the future in diverse situations, such as renal transplant rejection. In this issue Huber et al. demonstrate that rapamycin acts as an efficient inhibitor of lymphangiogenesis.
    Kidney International 05/2007; 71(8):717-9. DOI:10.1038/ · 8.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The mammalian target of rapamycin (mTOR) is an unconventional protein kinase that is centrally involved in the control of cancer cell metabolism, growth and proliferation. The mTOR pathway has attracted broad scientific and clinical interest, particularly in light of the ongoing clinical cancer trials with mTOR inhibitors. The mixed clinical results to date reflect the complexity of both cancer as a disease target, and the mTOR signaling network, which contains two functionally distinct mTOR complexes, parallel regulatory pathways, and feedback loops that contribute to the variable cellular responses to the current inhibitors. In this review, we discuss the regulatory pathways that govern mTOR activity, and highlight clinical results obtained with the first generation of mTOR inhibitors to reach the oncology clinics.
    Trends in Molecular Medicine 11/2007; 13(10):433-42. DOI:10.1016/j.molmed.2007.08.001 · 9.45 Impact Factor
Show more

Similar Publications